Humana, a prominent provider of Medicare Advantage health insurance for seniors, has announced its intention to sell its minority stake in a significant end-of-life care services provider for $900 million.
Divestiture Agreement for Gentiva Stake
Humana confirmed on Wednesday that it has entered into a definitive agreement with a consortium of investors to divest substantially all of its minority interest in Gentiva, recognized as the nation’s leading provider of end-of-life services, encompassing hospice and palliative care.
The proceeds from this sale are earmarked for general corporate purposes. The transaction is anticipated to be finalized in the third quarter of the current year, pending the satisfaction of various regulatory approvals.
Strategic Shift in Business Focus
This divestiture of Gentiva aligns with a strategic initiative Humana commenced several years ago, even prior to Jim Rechtin assuming the role of CEO. The company has been actively divesting various “non-core” assets within its Kindred At Home business, including hospice, palliative, and personal healthcare services.
Humana elaborated in a statement that in 2022, an agreement was reached to divest a majority interest in the Hospice and Personal Care divisions of its Kindred at Home subsidiary. These divisions were subsequently reorganized into a standalone entity and rebranded as Gentiva, which has since emerged as the largest provider of end-of-life care in the United States, serving over 430 locations across 35 states with a substantial workforce of clinicians and caregivers.
Expansion of Healthcare Services Segment
While Humana is widely recognized for its health insurance operations, particularly its Medicare Advantage plans serving over 6 million older adults, the company is making significant investments in its CenterWell healthcare services division under Rechtin’s leadership. This segment includes pharmacy, specialty pharmacy, and related distribution services.
CenterWell generated over $22 billion in revenue last year, contributing significantly to Humana’s total sales of $129.6 billion, according to the company’s latest financial report. Under Rechtin, the CenterWell business has increasingly concentrated on high-growth areas such as specialty and retail pharmacy. Notably, earlier this year, CenterWell Pharmacy and Mark Cuban’s Cost Plus Drug Company announced a partnership aimed at developing comprehensive employer prescription solutions.
Business Style Takeaway: Humana’s strategic divestiture of its Gentiva stake signals a clear pivot towards consolidating and investing in its core healthcare services, particularly the high-growth CenterWell division. This move allows for greater focus on integrated pharmacy and specialty services, potentially enhancing its competitive position in the evolving healthcare landscape.
Source: : www.forbes.com